03 jan: FLSmidth/Carnegie: Løfter til "køb"
03 jan: Bavarian får penge i kassen før tid - NY
03-01-2017 11:24:26

Bavarian Nordic Upgrades its Expectations for 2016 Year-end Cash Preparedness

Relateret indhold
26 jan - 
Bristol-Myers leverer svag indtjening og nedjusterer
17 jan - 
Tirsdagens aktier: Dong og Mærsk positive islæt i eller..
17 jan - 
Aktier/middag: Mærsk og Genmab i top mens markedet vent..
Relateret debat
08:15 - 
Enig og jf aftalen har de en meget kort periode til at ..
07:41 - 
Helt enig. Man skal også huske på at det er en optionsa..
20 feb - 
Tak for svar, og jeg vil supplere yderligere når vi bry..

COPENHAGEN, Denmark, January 3, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Company upgrades its expectations for the 2016 year-end cash preparedness from approximately DKK 1,900 million to approximately DKK 2,300 million. The upgrade is primarily a result of payments for IMVAMUNE deliveries, which have been received earlier than expected and to a minor extent the increased USD exchange rate as well as deferred investments. For 2016, the Company maintains its expectations for revenues of approximately DKK 1,000 million and a break-even result before interest and tax.

The full financial statements for 2016 will be published in the annual report on March 15, 2017.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 01 / 2017

2017-01-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-01-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 feb
BAVA
Der er såmænd nok ikke så mange herinde, der har en profession, der gør os til eskperter - og da sle..
13
20 feb
BAVA
  Jeg syntes det mdr for mdr ser bedre og bedre ud - markedet har en lidt anden mening - h..
6
19 feb
BAVA
Jeg ligger lang og er igen virkelig tanket i Bava, men vil alligevel nævne at der er andre Biotech d..
5
19 feb
BAVA
Efter min opfattelse er forskellen mellem Bavarian og alle andre at de har en "booster" som får emun..
4
20 feb
BAVA
For den BAVA-interesserede er i nedenstående link en interessant introduktion til PROSTVAC præsenter..
3
20 feb
BAVA
Fase III paapegyndtes i december 2011.....
2
17 feb
BAVA
Hva så venner, er i glade ?   Tiden går og patienterne lever. Kursen holdes "høj", selv ved lav omsæ..
2
20 feb
BAVA
Tak for opfølgning. Det er dejligt når der er nogen som holder tingene ajour. Det er for mig troværd..
1
20 feb
BAVA
Hvis du klikker ind og ser video fra youtube, står der at videoen er udgivet 6 marts 2015 :-)
1
20 feb
BAVA
Blot til info, så er det udgivet 6 marts, 2015. :)
1

Alternative investeringer hitter blandt de store

07-02-2017 10:29:17
​Sponsoreret indhold:Private investorer kan ligesom de professionelle få solide afkast og risikospredning med en investering i vindenergi. Ny guide viser dig, h..

DFDS: Stærk resultatfremgang, øget udbytte og nyt aktietilbagekøb

07-02-2017 08:41:33
Rederiet DFDS har haft betydelig resultatfremgang i 2016 og forkæler aktionærerne ved at øge udbyttet med en tredjedel og starte aktietilbagekøb for op til 800 ..

Maersk Line: Tysk opkøb får foden inden for i containeralliance

06-02-2017 15:01:11
Maersk Line har indgået en samarbejdsaftale med det tyske containerrederi Hamburg Süd, som Mærsk-koncernen købte i slutningen af 2016, men som kører videre unde..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Grækenland/Jyske: Det er en næsten håbløs situation
2
Vestas/vindforening: Det svenske marked bremser op
3
Jyske Bank/Sydbank: Havde ikke troet på så lave nedskrivninger - NY
4
Europa/formuepleje: Investorer føler usikkerhed inden europæiske valg
5
Mandagens aktier: Fortsat feriestemning mens Nets holdt dampen oppe

Relaterede aktiekurser

Bavarian Nordic A/S 278,50 0,0% Aktiekurs uændret
Bavarian Nordic DKK10 39,20 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. februar 2017 10:46:30
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB2 - 2017-02-21 10:46:30 - 2017-02-21 10:46:30 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x